Tag Archive for: Neuraxpharm Group

Weekly Roundup: Hot topics in the height of summer

/in

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease Minoryx Therapeutics and Neuraxpharm Group, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for NEZGLYAL® (leriglitazone) as a treatment for male […]

Read more

Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures

/in

A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real time, alerting patients and caregivers minutes before an episode occurs1 This breakthrough innovation represents a major milestone in Neuraxpharm’s commitment to advancing both digital and personalised solutions that enhance safety and improve quality of life […]

Read more
© Optimum Strategic Communications.